Acessibilidade / Reportar erro
Short Communication • Rev. Soc. Bras. Med. Trop. 51 (01) • Jan-Feb 2018 • https://doi.org/10.1590/0037-8682-0216-2017   copy

Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

INTRODUCTION

Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE.

METHODS

Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden’s factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed.

RESULTS

Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation.

CONCLUSIONS

Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.

Keywords:
Leprosy; Antiphospholipid antibodies; Beta-2-glycoprotein-I; Factor V Leiden; Prothrombin; Thromboembolism

Sociedade Brasileira de Medicina Tropical - SBMT Caixa Postal 118, 38001-970 Uberaba MG Brazil, Tel.: +55 34 3318-5255 / +55 34 3318-5636/ +55 34 3318-5287, http://rsbmt.org.br/ - Uberaba - MG - Brazil
E-mail: rsbmt@uftm.edu.br
Acompanhe os números deste periódico no seu leitor de RSS